How a Mutation Helps Cancer Evade the Immune System

Speedy Summary

• Study Findings: Research from UC davis identified an evolutionary mutation in a human immune protein, fas Ligand (FasL), making it susceptible to being neutralized by plasmin, a tumor-associated enzyme. This vulnerability is absent in non-human primates like chimpanzees.
• Tumor Mechanism: Plasmin disables FasL, which is critical for immune cells to kill cancerous cells via apoptosis. Elevated plasmin levels are common in aggressive solid tumors such as ovarian cancer and triple-negative breast cancer.
• Impact on Immunotherapy: The mutation explains why therapies like CAR-T and T-cell-based approaches perform well against blood cancers but struggle with solid tumors that utilize plasmin.
• Potential Solutions: Blocking plasmin or shielding FasL from enzymatic cleavage could restore its anti-tumor abilities. this could lead to improved immunotherapies for patients with solid tumors.

Indian Opinion Analysis

The findings highlight how evolutionary changes unique to humans may have unintended health implications, especially concerning our susceptibility to certain cancers. While this finding is rooted in basic biological differences between humans and non-human primates, its practical applications-such as using plasmin inhibitors or engineered antibodies-could revolutionize the treatment of previously resistant solid tumors. For India, where cancer rates are rising due to lifestyle changes and aging demographics, advancements in personalized immunotherapies hold significant promise. Moreover, integrating these research insights into local healthcare systems could enhance strategies against aggressive cancers prevalent among the population.

Read More